Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Nov 13, 2018	CareDx Announces Proposed Public Offering of Common Stock BRISBANE, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to	View HTML
Toggle Summary Nov 08, 2018	CareDx Reports Third Quarter Results AlloSure launch momentum drives 74% revenue growth BRISBANE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Nov 07, 2018	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML
Toggle Summary Oct 17, 2018	CareDx to Announce Third Quarter 2018 Financial Results on November 8, 2018 BRISBANE, Calif. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Oct 02, 2018	CareDx Profiles AlloSeq Suite of NGS Products at ASHI Expands portfolio with three new kitted transplant products launching in 2019 Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes Enables global access for laboratories to assess organ health by measuring	View HTML
Toggle Summary Sep 21, 2018	CareDx to Participate in Upcoming Investor Conference BRISBANE, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML
Toggle Summary Sep 17, 2018	CareDx broadens HeartCare availability Launches HeartCare registry to increase patient access to comprehensive surveillance solution of AlloMap and AlloSure Heart BRISBANE, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and	View HTML
Toggle Summary Aug 15, 2018	CareDx to Participate in Upcoming Investor Conference BRISBANE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML
Toggle Summary Aug 09, 2018	CareDx Reports Second Quarter Results AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Jul 16, 2018	CareDx to Announce Second Quarter 2018 Financial Results on August 9, 2018 BRISBANE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML